Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Zoledronic Acid Results Mixed for Advanced Breast Cancer

By Drug Discovery Trends Editor | December 15, 2010

Zoledronic acid did not improve disease free survival among women with stage 2/3 breast cancer according to results of the Adjuvant Treatment with Zoledronic Acid in Stage 2/3 Breast Cancer (AZURE) trial, which was presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

“In the larger population, we did not see a difference,” said Robert Coleman, M.D., professor of medical oncology at the University of Sheffield in England.

However, among 1101 patients who were five years post-menopause, about 30 percent of the overall group, there was a 29 percent improvement in overall survival. Coleman stressed that this was a secondary outcome, so it could not be considered conclusive, but it did present the largest unanswered question.

“To see a survival advantage like this is quite remarkable, and the difference in outcome between this group and the younger population is unlikely to be a chance finding. We will clearly want to investigate further in this population,” he said.

The AZURE trial included 3,360 patients with stage II/III breast cancer from 174 centers. Coleman and colleagues randomly assigned the patients to standard therapy or to standard therapy plus zoledronic acid. The primary outcome was disease free survival.

The researchers found no difference in disease free survival in the overall population.

“This will likely dissuade clinicians from giving adjuvant bisphosphonates on a routine basis to younger women taking adjuvant chemotherapy because, although the drug is generally well tolerated, there is a small risk of osteonecrosis of the jaw,” said Coleman.

The researchers identified 17 (1.1%) confirmed cases of osteonecrosis of the jaw over the duration of the study period.

These results do not impact on the current useage of zoledronic acid for the treatment of metastatic bone disease across a broad range of cancers.

Date: December 14, 2010
Source: American Association for Cancer Research 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE